PDLI Sublicenses Rights to Develop Antibody-Drug Conjugates for Prostate Cancer to DNA
Tweet Send to a Friend
Protein Design Labs, Inc. (Nasdaq: PDLI) sublicensed to Genentech, Inc. (NYSE: DNA) development and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
